BostonGene’s cloud-based software platform, bioinformatics capabilities, analytical tools, and advanced next-generation sequencing (NGS) support doctors in finding the most effective strategy for personalized treatment options for their patients.
BostonGene uses its state-of-the-art molecular testing laboratory to combine next-generation sequencing technologies. It integrates whole-exome sequencing, whole-transcriptome sequencing, multiplex immunofluorescence imaging, flow cytometry, bioinformatics, and analytics to produce comprehensive reports on the unique molecular portraits of tumors. This report equips doctors with all relevant information to identify personalized treatment plans.
Samples are processed at the BostonGene laboratory. The laboratory is CLIA and CAP accredited for DNA and RNA sequencing:
Certification Numbers
CLIA: 22D2182613
CAP: 8832984
The BostonGene platform integrates informatics, genomics, transcriptomics, and microenvironment analysis to empower personalized decisions and the delivery of optimized therapeutics.
BostonGene personalizes AI for medical experts to create a vast and continually updated database of biomarkers, therapies, clinical trials, and therapeutic guidelines.
